Home » Stocks » SNGX

Soligenix, Inc. (SNGX)

Stock Price: $0.953 USD -0.027 (-2.76%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
After-hours: $0.940 -0.013 (-1.35%) Jul 30, 5:53 PM
Market Cap 38.19M
Revenue (ttm) 1.58M
Net Income (ttm) -12.47M
Shares Out 36.82M
EPS (ttm) -0.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $0.953
Previous Close $0.980
Change ($) -0.027
Change (%) -2.76%
Day's Open 0.970
Day's Range 0.940 - 0.970
Day's Volume 124,015
52-Week Range 0.855 - 2.800

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Soligenix Demonstrates Clinical Success in First-in-Class Treatment for Cutaneous T-Cell LymphomaNew York, New York--(Newsfile Corp. - July 22, 2021) - PCG Digital -- Cutaneous T-cell lymphoma (CTCL) is...

1 week ago - Newsfile Corp

Reddit traders aren't just focused on short squeezes. Here are seven ultra-risky Reddit penny stocks that have caught their attention.

Other stocks mentioned: BLOZF, BTCY, TRYPF, UATG
2 weeks ago - InvestorPlace

New York, New York--(Newsfile Corp. - July 6, 2021) - PCG Digital -- A rare form of non-Hodgkin's lymphoma, cutaneous T-cell lymphoma (CTCL) has no current FDA-approved first-line therapies. There are r...

3 weeks ago - Newsfile Corp

PRINCETON, N.J., June 22, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...

1 month ago - PRNewsWire

PRINCETON, N.J., June 10, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...

1 month ago - PRNewsWire

PRINCETON, N.J., June 9, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to trea...

1 month ago - PRNewsWire

Company Connecting the Dots for Final FDA ApprovalNew York, New York--(Newsfile Corp. - June 3, 2021) - PCG Digital -- When Soligenix (NASDAQ: SNGX) updated its NDA rollout plan, the market quickly reac...

1 month ago - Newsfile Corp

PRINCETON, N.J., May 20, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to trea...

2 months ago - PRNewsWire

PRINCETON, N.J., May 17, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to trea...

2 months ago - PRNewsWire

Soligenix Inc (NASDAQ: SNGX) shares dropped during premarket after the company said it would not pursue a rolling marketing application submission for HyBryte (SGX301). Instead, it plans to submit the N...

2 months ago - Benzinga

PRINCETON, N.J., May 10, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to trea...

2 months ago - PRNewsWire

PRINCETON, N.J., May 4, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...

2 months ago - PRNewsWire

PRINCETON, N.J., April 28, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tr...

3 months ago - PRNewsWire

PRINCETON, N.J., April 26, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tr...

3 months ago - PRNewsWire

PRINCETON, N.J., April 13, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tr...

3 months ago - PRNewsWire

PRINCETON, N.J., April 7, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...

3 months ago - PRNewsWire

PRINCETON, N.J., March 30, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tr...

4 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - March 16, 2021) - PCG Digital -- The future is looking bright at Soligenix, Inc. In a corporate update released on February 24th, Dr. Christopher Schaber, Chairman,...

4 months ago - Newsfile Corp

PRINCETON, N.J., March 9, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...

4 months ago - PRNewsWire

Soligenix Inc (NASDAQ: SNGX) rises sharply in premarket trading after the publication of positive results from pre-clinical immunogenicity studies for the COVID-19 vaccine candidate, dubbed as CiVax. Th...

4 months ago - Benzinga

New York, New York--(Newsfile Corp. - February 23, 2021) - PCG Digital -- Operational efficiency and sound financial management lead to positive results. That statement sums up why Soligenix (NASDAQ: SN...

5 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - February 9, 2021) - PCG Digital: Soligenix (NASDAQ: SNGX) continues to build excitement for its SGX301 candidate following strong Phase 3 data and commercialization...

5 months ago - Newsfile Corp

PRINCETON, N.J., Feb. 1, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to trea...

5 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - January 25, 2021) - PCG Digital: Advancing health care innovation is a cornerstone of thorough public health policy. Researching and developing new treatments for u...

6 months ago - Newsfile Corp

PRINCETON, N.J., Jan. 19, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...

6 months ago - PRNewsWire

PRINCETON, N.J., Jan. 7, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to trea...

6 months ago - PRNewsWire

PRINCETON, N.J., Dec. 28, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...

7 months ago - PRNewsWire

PRINCETON, N.J., Dec. 22, 2020 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...

7 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - December 9, 2020) -  The COVID-19 pandemic has been one of the most significant "black swan" events in recent history. As of early December 2020, around 1.5 million...

7 months ago - Newsfile Corp

PRINCETON, N.J., Nov. 12, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...

8 months ago - PRNewsWire

PRINCETON, N.J., Nov. 10, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...

8 months ago - PRNewsWire

Positive Phase 3 data reported on Oct. 22, solidifies the approvability of SGX301 for CTCL treatment, an estimated $250M annual revenue opportunity, yet SNGX's valuation is only ~$55M. SGX942 for oral m...

9 months ago - Seeking Alpha

PRINCETON, N.J., Oct. 8, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to trea...

9 months ago - PRNewsWire

PRINCETON, N.J., Sept. 15, 2020 /PRNewswire/ -- Soligenix, Inc.

10 months ago - PRNewsWire

PRINCETON, N.J., Sept. 10, 2020 /PRNewswire/ -- Soligenix, Inc.

10 months ago - PRNewsWire

PRINCETON, N.J., Sept. 3, 2020 /PRNewswire/ -- Soligenix, Inc.

10 months ago - PRNewsWire

PRINCETON, N.J., Aug. 27, 2020 /PRNewswire/ -- Soligenix, Inc.

11 months ago - PRNewsWire

PRINCETON, N.J., Aug. 14, 2020 /PRNewswire/ -- Soligenix, Inc.

11 months ago - PRNewsWire

Soligenix: Multiple Shots On Goal, Strong Evidence Of Success, And Attractive Valuation

1 year ago - Seeking Alpha

PRINCETON, N.J., July 20, 2020 /PRNewswire/ -- Soligenix, Inc.

1 year ago - PRNewsWire

Soligenix (NASDAQ: SNGX) shares were trading higher on Friday after the company completed enrollment in its Phase 3 clinical trial of SGX942 for the treatment of oral mucositis.

1 year ago - Benzinga

PRINCETON, N.J., June 22, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...

1 year ago - PRNewsWire

PRINCETON, N.J., June 9, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to trea...

1 year ago - PRNewsWire

PRINCETON, N.J., May 15, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to trea...

1 year ago - PRNewsWire

Soligenix's Upcoming Catalyst For Pipeline Product SGX301 Could Offer A Nice Trade Opportunity

1 year ago - Seeking Alpha

Shares of rare disease biopharma Soligenix, Inc. (NASDAQ: SNGX) were spiking higher Thursday after the company announced a coronavirus-related licensing agreement.

1 year ago - Benzinga

Soligenix: Two Phase-3 Clinical Trials - Results By June 2020

1 year ago - Seeking Alpha

Soligenix is a small biotech company with just ~$20M market cap.

1 year ago - Seeking Alpha

About SNGX

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301, a novel photodynamic therapy, which has completed Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial to treat oral mucositis in head and neck cancer. This se... [Read more...]

Industry
Biotechnology
IPO Date
Jun 15, 1987
CEO
Christopher Schaber
Employees
17
Stock Exchange
NASDAQ
Ticker Symbol
SNGX
Full Company Profile

Financial Performance

In 2020, Soligenix's revenue was $2.36 million, a decrease of -49.04% compared to the previous year's $4.63 million. Losses were -$17.69 million, 89.1% more than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Soligenix stock is "Buy." The 12-month stock price forecast is 3.81, which is an increase of 299.79% from the latest price.

Price Target
$3.81
(299.79% upside)
Analyst Consensus: Buy